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Abstract
Purpose Whether an unfavorable lifestyle not only affects breast cancer risk, but also influences age at onset of breast cancer 
and survival, is under debate.
Methods In a population-based cohort, the Energy Balance and Breast Cancer Aspects throughout life (EBBA-Life) study, 
a total of 17,145 women were included. During follow-up, 574 women developed invasive breast cancer. Breast cancer cases 
were followed for an additional 9.1 years. Detailed medical records were obtained. Cox’s proportional hazard regression 
models were used to study the association between pre-diagnostic lifestyle factors (weight, physical activity, alcohol use, 
smoking, and hypertension), breast cancer risk, age at diagnosis, and survival.
Results At study entry, 34.3% of the participating women were overweight and 30.7% were physically inactive. Mean age 
at breast cancer diagnosis was 58.0 years, and 78.9% of the tumors were estrogen receptor positive. Among menopausal 
women who did not use hormone therapy and had an unfavorable lifestyle (3–5 unfavorable factors), compared with women 
who had a favorable lifestyle, we observed a twofold higher risk for postmenopausal breast cancer (hazard ratio [HR] 2.13, 
95% confidence interval [CI] 1.23–3.69), and they were 3.4 years younger at diagnosis (64.8 versus 68.2 years, P = 0.032). 
Breast cancer patients with an unfavorable lifestyle, compared with patients with a favorable lifestyle, had almost a two times 
higher overall mortality risk (HR 1.96, 95% CI 1.01–3.80).
Conclusions Our study supports a healthy lifestyle improving breast cancer prevention, postponing onset of disease, and 
extending life expectancy among breast cancer patients.
Keywords Lifestyle · Breast cancer · Onset · Risk · Survival
Introduction
A global increase in breast cancer incidence has been 
observed, with incidence rates being almost fourfold higher 
in the developed than in the less-developed countries, 
emphasizing that large differences in lifestyle may have an 
important role to play [1]. Of note, the rates of estrogen 
receptor (ER)-positive breast cancer incidence are increasing 
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[2], suggesting that an estrogen-dependent mechanism links 
unfavorable lifestyle to this most common breast cancer 
subtype. Furthermore, life expectancy for women who have 
survived breast cancer has been observed to be shorter com-
pared with women in the general population [3], but whether 
lifestyle factors play a key role in relation to breast cancer 
survival remains ambiguous.
The association between body composition, including 
body weight and breast cancer risk, is well known. High 
Body Mass Index (BMI) has been positively associated with 
postmenopausal breast cancer [4, 5], but most studies report 
that excess body weight is inversely related to premenopau-
sal breast cancer risk [6]. Obesity has also been associ-
ated with reduced breast cancer survival [7]. A physically 
active lifestyle compared with a sedentary lifestyle has been 
observed to reduce both pre- and postmenopausal breast 
cancer risk overall [8, 9]. The association between physical 
activity and breast cancer survival is still being debated [9]. 
The most consistent dietary risk factor for breast cancer is 
alcohol [10, 11]. Alcohol intake has been associated with 
higher estradiol levels and higher mammographic density 
[12], and both pre- and postmenopausal breast cancer risk 
[13, 14]. Recent meta-analysis observed a positive associa-
tion between hypertension and breast cancer risk [15, 16]. 
Moreover, a new cohort study reported a positive associa-
tion between hypertension and breast cancer mortality after 
adjustments [17], supporting hypertension as an independent 
risk factor linked to breast cancer. Tobacco smoking pos-
sesses potential mammary carcinogens [18], and recently 
tobacco use showed an increased risk for ER-positive breast 
cancer [19].
Possible biological mechanisms operating for most of 
these lifestyle factors may be mediated by adipose tissue, 
with low-grade chronic inflammation creating an environ-
ment that promotes breast cancer development and growth 
[20–22]. Another potential mechanism linking these factors 
is via increased estrogen levels, a key component in breast 
cancer development [9]. In addition, both hypertension and 
breast cancer development may act through activation of 
the renin-angiotensin system [23]. The proposed pathophysi-
ological processes related to unfavorable lifestyle factors, 
e.g., chronic inflammation and insulin resistance, are also 
established biological mechanisms associated with aging, a 
known risk factor for cancer development [24]. Moreover, 
a rising trend within the general population of being over-
weight appears to parallel a shift to the appearance of cancer 
at an earlier age [25]; this suggests that obesity and other 
unfavorable lifestyle factors not only promote tumor growth, 
but also affect aging and breast cancer onset. Hence, one 
may hypothesize that lifestyle factors play a role in relation 
to optimal breast cancer treatment, comorbidity, and breast 
cancer survival.
The main aim of the present study was, therefore, based 
on a population-based cohort study, with a high attendance 
rate and detailed medical and histopathological information, 
to explore the joint effect of lifestyle factors on breast cancer 
risk, age at onset, and survival.
Materials and methods
This population-based cohort, the Energy Balance and 
Breast Cancer Aspects throughout life (EBBA-Life) study 
[26, 27], is a substudy of the Tromsø study [28]. A total of 
20,619 women, aged > 20 years, participated in the popula-
tion-based Tromsø study in five waves of almost identical 
data collection, conducted between 1986 and 2016, carried 
out 6–7 years apart with an attendance rate of 74.0% [28, 
29]. At study entry, all participants completed questionnaire 
data and sampling of biological specimens, and basic clini-
cal measurements were performed. All data collection was 
carried out by trained research technicians at each survey.
Questionnaires
The questionnaires were filled in at home and brought to the 
study site, where they were checked for completeness and 
inconsistency. Questionnaires included items about medical 
history, specific symptoms, dietary habits, lifestyle factors, 
reproductive factors, and use of medication including anti-
hypertensive drugs and hormone therapy [28].
Assessment of lifestyle factors and menopausal 
hormone therapy (MHT)
Height and weight were measured [28], and the BMI (kg/
m2) was calculated. Physical activity was reported accord-
ing to type of physical activity over the last 12 months 
(walking/cycling, recreational sport, strenuous training, or 
participating in sports competition), duration, and hours of 
intensity exercise per week. Categories of physical activity 
were classified as follows: (1) sedentary physical activ-
ity: reading/sitting with no participation in recreational 
sport activities or competitions over the last 12 months; 
(2) moderate physical activity: walking/cycling at least 
4 h a week and/or minimum of 1 h of strenuous physical 
activity per week (sweating/out of breath); and (3) hard 
physical activity: participating in strenuous training or 
sports competitions regularly/several times a week and/
or exercise approximately every day. Alcohol intake was 
reported according to the number of days a month when 
alcohol was drunk, and has been validated [30]. Smoking 
was reported and classified as never/past smokers or cur-
rent smokers. Blood pressure (mmHg) was measured [28]. 
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MHT use was reported and classified as past/present use or 
never use. Baseline information on MHT use was obtained 
when the participants first entered the study, and updated 
MHT use was performed at each new wave between 1986 
and 2016.
Identification of breast cancer cases, breast tumor 
characteristics, and medical charts
All breast cancer cases were identified through linkage 
to the Cancer Registry of Norway by using the unique, 
national, 11-digit identification number [31]. We obtained 
information on death and emigration from the Cause of 
Death Registry and the National Population Registry, 
respectively [32, 33]. Death from breast cancer was coded 
according to International Classification of Disease (ICD) 
[34]. We excluded all attendees who had a previous his-
tory of cancer, or who emigrated, died, or were diagnosed 
with cancer within the first year after study entry (n = 709). 
All women with missing information on BMI, physical 
activity, alcohol use, smoking, blood pressure, or MHT 
use were excluded (n = 2 765). Thus, 17,145 women were 
included in the final sample. The participants were fol-
lowed from the date of entry into the study until the date of 
breast cancer diagnosis, date of emigration, date of death, 
or end of follow-up (December 31, 2017), whichever event 
occurred first.
The breast cancer patients’ medical charts were 
reviewed to obtain detailed clinical data, including breast 
cancer histological type, grade (1–3), tumor stage (1–4) 
according to the TNM (tumor, node, metastases) classifi-
cation, and breast cancer treatment. A total of 574 women 
were diagnosed with incident invasive breast cancer during 
follow-up (Online Resource 1). Follow-up after breast can-
cer diagnosis was calculated from the date of the diagnosis 
to the date of death, emigration, or end of follow-up.
All breast tumor samples were fixed in 4% buffered 
formaldehyde before processing and embedding in paraf-
fin. To obtain more complete and updated information on 
tumor characteristics, most (n = 407) of the tissue samples 
were analyzed on tissue microarrays (TMAs) at the Uni-
versity of Bergen, Norway (Centre for Cancer Biomarkers) 
[26, 35]. Breast tumor specimens not reanalyzed on TMA 
blocks (n = 167) were evaluated using immunohistochem-
istry for hormone receptor status and Ki-67, and immu-
nohistochemistry and fluorescence in situ hybridization 
for human epidermal growth factor receptor-2 (HER2). A 
subset of the breast cancer cases (n = 522) with complete 
information on receptor status were categorized into three 
molecularly defined subgroups: (1) ER positive—patients 
with ER-positive (with or without progesterone (PgR)-pos-
itive) and HER2-negative status; (2) HER2 positive—all 
patients with HER2 overexpression; and (3) triple-negative 
breast cancer (TNBC)—HER2−, ER-−, and PgR-negative 
status.
Statistical methods
To characterize the change in incidence rates during fol-
low-up, crude incidence rates were calculated as new 
breast cancer cases per 1000 person-years at risk for dis-
ease for the total cohort (30–90 years) and within the age 
groups: ≤ 55 years and > 55 years. Non-linearity in incidence 
trends was considered and an estimate calculated using a 
fractional polynomial in Poisson’s regression models. A total 
of 44 models were estimated to find the best-fitting model to 
describe trends in breast cancer incidence.
Multivariable Cox’s proportional hazard regression mod-
els were used to study whether a pre-diagnostic unfavorable 
lifestyle, assessed at baseline, was associated with breast 
cancer risk and mortality. To study the importance of the 
variation in lifestyle factors independently and in combina-
tion, we identified five different modifiable lifestyle-related 
factors associated with breast cancer development, and cat-
egorized each of them into favorable versus unfavorable 
based on international categorization (WCRF/AICRF, World 
Health Organization) [36, 37]:
1. Body composition favorable—BMI < 25 kg/m2 versus 
unfavorable—BMI ≥ 25 kg/m2.
2. Physical activity favorable—moderate or more physical 
activity versus unfavorable—sedentary physical activity.
3. Alcohol use favorable—no alcohol or ≤ 1 day a month 
drinking alcohol versus unfavorable— > 1 day a month 
drinking alcohol.
4. Smoking favorable—no current smoking versus unfa-
vorable—current smoker.
5. Hypertension favorable—systolic blood pres-
sure < 140 mmHg, diastolic blood pressure < 90 mmHg, 
and no antihypertensive medication versus unfavora-
ble—systolic blood pressure ≥ 140 mmHg and/or dias-
tolic blood pressure ≥ 90 mmHg, and/or use of antihy-
pertensive medication.
The participants scored 0 for each favorable lifestyle fac-
tor and 1 for each unfavorable one, resulting in a score range 
of 0–5. We then split these modifiable lifestyle factors into 
four categories according to the sum of unfavorable life-
style factors: category 1 (reference): score 0; category 2, 
score 1; category 3, score 2; category 4, score 3–5. We con-
structed three separate regression models for each exposure 
to evaluate overall, premenopausal, and postmenopausal 
breast cancer as model-specific outcomes. Based on previous 
studies among women from the same cohort [27], premeno-
pausal status was defined as age ≤ 55 years, and all women 
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aged > 55 years were categorized as postmenopausal. MHT 
use is a strong risk factor for breast cancer, and therefore 
we ran separate time-dependent regression analyses accord-
ing to updated information on MHT use during follow-up. 
We used a linear regression model to study the association 
between clustering of unfavorable lifestyle factors and age 
at diagnosis. One-way analysis of variance (ANOVA) was 
used to study the differences between number of unfavorable 
lifestyle factors and breast tumor characteristics.
Based on suggested biological mechanisms influencing 
these modifiable lifestyle factors and/or breast cancer risk 
and prognosis, several variables were studied as potential 
confounders: age (continuous), age at menarche (continu-
ous), and number of live births (continuous). In the final 
analysis of survival, only age was included as a potential 
confounder. Breast cancer stage (categorical) did not influ-
ence our results, and was not included. A total of 111 breast 
cancer cases were checked for agreement between subtyping 
based on immunohistochemistry and TMA. We observed an 
agreement between these two methods in 93% of the breast 
cancer cases (κ = 0.76). All the tests were two sided and the 
statistical significance was defined by P < 0.05. Statistical 
analyses calculating crude incidence of new breast cancer 
cases were conducted using STATA 14 (StataCorp, College 
Station, TX, USA). All other statistical analyses were con-
ducted using SPSS 21.0 (IBM Corporation, Armonk, NY, 
USA).
Results
Among the 17,145 women included at study entry, 34.3% 
were overweight, 30.7% physically inactive, and 58% con-
sumed alcohol > 1 day/month. We observed a 93% increase 
in overall age-adjusted breast cancer incidence through the 
period from 1995 to 2017 (incidence rate ratio 1.93, 95% 
CI 1.42–2.62) (Fig. 1). Mean age at breast cancer diagnosis 
was 58.0 (range 31.2–92.0) years, and 78.9% of the breast 
Fig. 1  Breast cancer incidence rate in the period between 1995 and 2017 among: a women aged 30–90 years, b women aged 30–55 years, and c 
women aged 55–90 years
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Table 1  Characteristics of women without breast cancer (non-cases) and breast cancer patients (cases): the EBBA-Life study (1986–2017)
BMI Body Mass Index (kg/m2), HER2 human epidermal growth factor receptor-2, MHT menopausal hormone therapy, NST no special type, SD 
standard deviation
a Numbers may vary due to missing information
b MHT users at baseline
c Overweight defined as BMI ≥ 25 kg/m2
d Physically inactive: reading/sitting with no participation in recreational sport activities or competitions during the last 12 months
e Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, and/or use of antihypertensive medication
All women (n = 17,145)a Non-cases (n = 16 571)a Breast cancer 
cases (n = 574)a
Mean (SD)/% Mean (SD)/% Mean (SD)/%
Characteristics at study entry
 Age at attendance, years 41.7 (13.8) 41.7 (13.8) 41.3 (12.4)
 Follow-up, years 20.1 (10.0) 20.2 (11.1) 16.7 (7.85)
 Overall mortality rate, % 14.3 13.9 26.3
Reproductive factors
 Number of children 2.11 (1.36) 2.11(1.36) 2.03 (1.26)
 Age at menarche, years 13.2 (1.47) 13.2 (1.47) 13.1 (1.43)
Clinical variables
 Height, cm 164 (6.58) 164 (6.57) 165 (6.06)
 BMI, kg/m2 24.4 (4.34) 24.4 (4.36) 23.7 (3.63)
 Systolic blood pressure, mmHg 122 (19,0) 122 (19.1) 122 (17.6)
 Diastolic blood pressure, mmHg 72.4 (10.9) 72.3 (11.0) 73.3 (10.7)
Lifestyle factors/Comorbidity
 MHT  usersb, % 4.5 4.5 4.2
 Blood pressure treatment, % 4.99 5.02 4.08
 Overweightc, % 34.3 34.6 27.1
 Physically  inactived, % 30.7 30.6 32.3
 Alcohol consumption > 1 day/month, % 58.1 58.3 52.7
 Current smokers, % 41.0 40.9 44.2
 Hypertensione, % 18.2 18.2 18.0
Characteristics among breast cancer cases
 Age at diagnosis, years 58.0 (11.7)
 Observation time after diagnosis, years 9.11 (6.91)
 Cancer-specific mortality rate, % 9.8
Tumor characteristics
 Histological subtype, %
 Invasive carcinoma NST 79.7
 Invasive lobular carcinoma 13.1
 Others 7.2









 Estrogen receptor positive, % 78.9
 Progesterone receptor positive, % 59.8
 HER2 positive, % 16.3
 Ki-67, % 20.6 (17.8)
Treatment
 Chemotherapy, % 36.0
 Endocrine therapy, % 40.9
 Radiation therapy, % 78.5
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tumors were ER positive (Table 1). The distribution of 
the molecularly defined breast cancer subtypes was as fol-
lows: ER positive (69.5%, n = 362), HER2 positive (16.3%, 
n = 85), and TNBC (14.2%, n = 75) (Online Resource 2).
Pre‑diagnostic lifestyle factors: breast cancer risk
Among all the women, those drinking alcohol > 1 day/month 
versus those drinking alcohol 0–1 day/month had a 31% 
higher overall breast cancer risk (hazard ratio [HR] 1.31, 
95% CI 1.10–1.56). Current smoking versus no/previous 
smoking was associated with a 30% decreased premenopau-
sal breast cancer risk (HR 0.70, 95% CI 0.53–0.91) (Table 2).
Among women who were MHT non-users, those with 
three to five unfavorable lifestyle factors versus those with 
no unfavorable lifestyle factors had more than a twofold 
increased risk of developing postmenopausal breast cancer 
(HR 2.13, 95% CI 1.23–3.69) (Table 2). No clear association 
was observed between clustering of unfavorable lifestyle fac-
tors and premenopausal breast cancer risk (Table 2).
After stratification by breast cancer molecular subtype, 
women with three to five unfavorable lifestyle factors ver-
sus no unfavorable lifestyle factors had a 43% increased 
ER-positive breast cancer risk (HR 1.43, 95% CI 0.97–2.10, 
Ptrend = 0.096). Among postmenopausal women who were 
MHT non-users, those with three to five unfavorable lifestyle 
factors versus no unfavorable lifestyle factors had a 142% 
increased risk for ER-positive postmenopausal breast can-
cer (HR 2.42, 95% CI 1.27–4.63) (Online Resource 3). No 
association was observed between clustering of unfavorable 
lifestyle factors and HER2-positive cancer and TNBC over-
all (Online Resource 2).
Pre‑diagnostic lifestyle factors: age at diagnosis
Among MHT non-users who developed postmenopausal 
breast cancer, women with three to five unfavorable life-
style factors were 3.4 years younger at diagnosis than those 
with no unfavorable lifestyle factors (64.8 years versus 
68.2 years, P = 0.032) (Table 3). Furthermore, these MHT 
non-users with three to five unfavorable lifestyle factors had 
larger tumors than those with no unfavorable lifestyle factors 
(26.3 versus 12.3 mm, P = 0.023). Other tumor characteris-
tics were not statistically differently distributed throughout 
Table 2  Age-adjusted hazard ratios for incident breast cancer overall and according to menopausal status and MHT use
Cox proportional hazard model
Adjusted to age, age at menarche, and number of live births
CI confidence interval, HR Hazard ratio, MHT menopausal hormone therapy, n number of cases, ref reference
a Overweight defined by BMI ≥ 25 kg/m2
b Physical inactivity defined by reading/sitting with no participation in recreational sport activities or competitions during last 12 months
c Alcohol use defined by > 1 day of alcohol use per month
d Current cigarette smoking
e Hypertension defined by systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg, and/or use of antihypertensive medi-
cation
All breast cancers Premenopausal breast cancer Postmenopausal breast cancer
MHT non-users MHT users
n = 574 HR (95% CI) n = 246 HR (95% CI) n = 237 HR (95% CI) n = 91 HR (95% CI)
Modifiable lifestyle factors
 Overweighta 0.92 (0.75–1.12) 0.88 (0.64–1.23) 1.16 (0.86–1.55) 0.88 (0.53–1.33)
 Physical  inactivityb 1.07 (0.90–1.29) 1.20 (0.90–1.59) 1.10 (0.81–1.48) 0.79 (0.51–1.23)
 Alcohol  usec 1.31 (1.10–1.56) 1.05 (0.80–1.38) 1.57 (1.20–2.06) 1.18 (0.82–1.71)
 Cigarette  smokingd 0.94 (0.79–1.12) 0.70 (0.53–0.91) 1.16 (0.89–1.59) 1.11 (0.77–1.16)
 Hypertensione 0.97 (0.67–1.13) 1.17 (0.72–1.90) 0.85 (0.60–1.21) 1.00 (0.60–1.68)
Number of unfavorable lifestyle factors
 0 (ref) 62 1.00 34 1.00 17 1.00 11 1.00
 1 200 1.41 (1.04–1.78) 91 1.05 (0.71–1.55) 71 1.66 (0.97–2.83) 38 1.58 (0.86–2.92)
 2 176 1.26 (0.93–1.71) 79 0.90 (0.60–1.34) 72 1.72 (1.01–2.93) 26 1.29 (0.67–2.45)
 3–5 136 1.34 (0.97–1.85) 42 0.83 (0.53–1.31) 77 2.13 (1.23–3.69) 17 1.22 (0.60–2.52)
Ptrend 0.348 0.222 0.011 0.999
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the four categories of unfavorable lifestyle factors (Online 
Resource 4).
Pre‑diagnostic lifestyle factors: overall mortality 
and breast cancer‑specific mortality
Among all breast cancer cases combined, we observed a 96% 
increased overall mortality risk for those breast cancer cases 
with three to five unfavorable lifestyle factors versus no unfa-
vorable lifestyle factors (HR 1.96, 95% CI 1.01–3.80) (Table 4, 
Fig. 2). A positive trend between clustering of unfavorable 
lifestyle factors and overall mortality was observed among pre-
menopausal breast cancer patients (Ptrend = 0.020) (Table 4). 
Among postmenopausal women, we observed a sugges-
tively inverse trend between clustering of unfavorable lifestyle 
factors and breast cancer mortality (Ptrend = 0.050) (Table 4). 
Discussion
In this population-based cohort we observed, over 20 years 
of follow-up, a 93% increased breast cancer incidence. 
Furthermore, among women who had a clustering of pre-
diagnostic unfavorable lifestyle factors, compared with 
women who had a favorable lifestyle, we demonstrated a 
twofold increase in postmenopausal breast cancer risk. 
Table 3  Age at diagnosis among breast cancer patients according to number of unfavorable lifestyle factors by menopausal status at diagnosis 
and MHT use
Linear regression model
Covariates: Age at study entry
CI confidence interval, MHT menopausal hormone therapy, n number of cases, SE standard error
a Unfavorable lifestyle factors: overweight, physical inactivity, alcohol use, smoking, and hypertension
b p value reflecting difference between no unfavorable lifestyle factors and three to five unfavorable lifestyle factors
All breast cancers Premenopausal breast cancer Postmenopausal breast cancer
MHT non-users MHT users
n = 574 Age at diagnosis (SE) n = 246 Age at diagnosis (SE) n = 237 Age at diagnosis (SE) n = 91 Age at diagnosis (SE)
Number of unfavorable lifestyle  factorsa
 0 62 58.8 (0.97) 34 49.2 (0.80) 17 68.2 (1.37) 11 63.0 (1.53)
 1 200 58.5 (0.54) 91 47.5 (0.48) 71 66.7 (0.68) 38 65.1 (0.81)
 2 176 57.4 (0.57) 79 46.6 (0.52) 72 65.7 (0.67) 26 66.0 (0.97)
 3–5 136 58.0 (0.67) 42 48.6 (0.72) 77 64.8 (0.68) 17 65.6 (1.23)
 Pb 0.517 0.585 0.032 0.198
Table 4  Age-adjusted hazards ratios between lifestyle and overall and breast cancer mortality by menopausal status
Multivariable Cox proportional hazard regression models
Adjusted for age (continuous)
CI confidence interval, HR Hazard ratio, n number of cases, ref reference
All breast cancer cases (n = 574) Premenopausal breast cancer (n = 245) Postmenopausal breast cancer (n = 329)


















HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Number of unfavorable lifestyle factors
 0 (ref) 62 1.00 1.00 34 1.00 1.00 28 1.00 1.00



































 Ptrend 0.005 0.874 0.020 0.260 0.553 0.050
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This increased breast cancer risk was restricted to MHT 
non-users, and confined to the most common breast cancer 
subtype: ER-positive breast tumors. Moreover, postmeno-
pausal women with a pre-diagnostic unfavorable lifestyle 
were 3.4 years younger at breast cancer diagnosis compared 
with women who had a favorable lifestyle. Our study also 
demonstrated that a pre-diagnostic unfavorable lifestyle was 
associated with almost a two times higher overall mortality 
risk among women with breast cancer.
Our observed results extend previous studies, but are also 
in part supported by others [38, 39]. The steady increase in 
breast cancer incidence over the last three decades observed 
in our cohort is in line with findings in comparable popu-
lations [1]. Of note, an increased breast cancer incidence 
observed in the present study is unlikely to have been 
influenced by any breast cancer-screening program intro-
duced many years ahead [40].
Our findings of a dose–response association between a 
joint combination of lifestyle factors and breast cancer risk 
with a twofold increase in postmenopausal breast cancer risk 
among women with an unfavorable lifestyle are supported 
[41–44]. In a large prospective study including mainly 
postmenopausal women [45], adherence to dietary guide-
lines [46] was associated with a decreased breast cancer 
risk, in particular ER-positive breast cancer tumors. In the 
Nurse’s Health Study cohort, a decreased postmenopausal 
breast cancer risk was observed, especially for ER-positive 
breast cancer, among women with the lowest weight gain, 
no alcohol consumption, high physical activity level, and 
had no MHT use [47]. Moreover, postmenopausal women 
Fig. 2  Women diagnosed with 
breast cancer in the EBBA-Life 
study (n = 574). Number of 
unfavorable lifestyle factors and 
a overall mortality, and b breast 
cancer mortality Adjusted for 
age
223Breast Cancer Research and Treatment (2020) 182:215–227 
1 3
who participated in the Norwegian Breast Cancer Screening 
Program, self-reported lifestyle factors were associated with 
increased risk for ER-positive luminal A-like and luminal 
B-like HER2-positive breast cancer [48]. Of note, MHT use 
has been documented as a strong independent risk factor for 
breast cancer development [49]. This underlines the impor-
tance of investigating the clustering of modifiable lifestyle 
factors stratified by MHT users and non-users [49–51]. How-
ever, the well-defined interaction between obesity, physical 
inactivity, and breast cancer among MHT non-users and not 
among MHT users is not generally present for alcohol [52] 
and smoking [53]. It is of interest that, in a recent study 
among women participating in the UK Biobank study, a 
healthy lifestyle, including diet, physical activity, smok-
ing, alcohol intake, and body composition, was observed 
to attenuate the impact of genetic factors on invasive breast 
cancer risk [54]. In our age-adjusted regression analysis pre-
senting the lifestyle factors, smoking was inversely related to 
premenopausal breast cancer risk, in contrast to other studies 
[55]. Our observation may be a chance finding, and based 
on recent observations and potential biological mechanisms 
operating, we chose to include smoking as a lifestyle-asso-
ciated breast cancer risk factor.
To our knowledge, our results showing an association 
between an unfavorable lifestyle and earlier age at diagnosis 
of sporadic breast cancer have not previously been reported 
in a population-based cohort study. However, in a recent 
study weight gain was associated with earlier age at diag-
nosis [56]. Moreover, one early study showed that among 
BRCA1/BRCA2 mutations carriers, physical exercise and 
healthy weight were associated with delayed age at breast 
cancer onset [57]. Hence, previous results and our results 
suggest that an unfavorable lifestyle may promote tumor 
growth and alter breast cancer onset in both BRCAI/II muta-
tion carriers and in those at risk of sporadic breast cancer.
In our study, we observed that a pre-diagnostic unfa-
vorable lifestyle was associated with an almost two times 
higher overall mortality. An association between obesity 
and more advanced stage and higher grade at diagnosis 
among postmenopausal breast cancer patients has been 
found [58]. We observed that women with postmenopausal 
breast cancer who were MHT non-users and had an unfa-
vorable lifestyle, including being overweight, were likely to 
have larger tumors compared with women with a favorable 
lifestyle. However, larger tumor size at diagnosis among 
postmenopausal breast cancer patients was not translated 
into shortened breast cancer-specific survival in our study. 
The association between an overall unfavorable lifestyle and 
higher overall mortality risk may reflect that an unfavora-
ble lifestyle is often associated with other comorbid condi-
tions [59, 60]. Consequently, breast cancer patients, even 
if they are cured of their cancer, may experience a reduced 
overall life expectancy due to pre-existing susceptibility to 
comorbidities and late adverse effects of treatment [61, 62]. 
This may, in particular, play a role for young breast can-
cer patients, as they tend to present with more aggressive 
tumor characteristics [63], which requires more comprehen-
sive treatment, putting these women at risk of developing 
more severe treatment-induced chronic adverse effects [64]. 
Hence, the potential long period of post-diagnostic survival 
for most breast cancer patients provides a context in which 
long-term exposure to an unfavorable lifestyle may have a 
substantial impact on morbidity and overall mortality. Of 
note, we observed, among women with postmenopausal 
breast cancer, an inverse association between pre-diagnos-
tic unfavorable lifestyle and breast cancer mortality. This 
observation may reflect that postmenopausal women with 
an unfavorable lifestyle are prone to die of causes other than 
their breast cancer [65].
The exact biological mechanisms explaining the associa-
tion between lifestyle and breast cancer development have 
yet to be established, but an unfavorable lifestyle may accel-
erate aging and increase tumor growth, and result in chronic 
inflammation, metabolic dysfunction, and DNA methylation 
[66–68]. Telomere length has been proposed as a biomarker 
of biological age and a risk factor for cancer [69]. The unfa-
vorable lifestyle factors included in our study have been 
independently observed to shorten telomere length, lead-
ing to accelerated aging [70–73], and potentially influence 
breast cancer prognosis [74]. An association between tel-
omere length and breast cancer risk has shown conflicting 
results [75, 76]. However, one may propose that a healthy 
lifestyle may reduce the pace of telomere shortening, and 
delay the onset of age-related diseases, including breast can-
cer. In addition, high elevated levels of advanced glycation 
end products, observed in ER-positive breast cancers, have 
been associated with physical inactivity, tumor growth, and 
therapy resistance [77].
Our study had several strengths, which include its pop-
ulation-based approach, high attendance rate, the use of a 
standardized protocol for data collection, and measured 
height and weight. The study had high completeness rates 
of identification of breast cancer cases (Cancer Registry 
of Norway), and identification of death and emigration 
(Cause of death Registry). In an evaluation of the data 
quality of the Cancer Registry of Norway, completeness 
of reporting was estimated to be very high, 98.8% [31], 
limiting the possibility for any misclassification related to 
identification of cases. Thus, it is less likely that loss to 
follow-up or inadequate reporting influences our risk esti-
mate, further reducing the chance of biased observations. 
Moreover, to lessen the chance that undiagnosed cancer 
could influence our results, we limited our study popula-
tion to women who had no history of previous breast or 
other cancer within the first year after study inclusion. 
All medical records for the breast cancer patients were 
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carefully reviewed by trained physicians, and included 
systematic abstraction of histopathology, oncological 
treatment, and recurrence and death [27]. The study also 
has several limitations. We did not have data on age at 
first pregnancy, family history of disease, weight at young 
adulthood, and adult weight gain. Moreover, the lifestyle 
factors and other baseline variables, except menopausal 
hormone therapy use, were based on a single pre-diagnos-
tic measure collected average 20.1 years before censored. 
Thus, we were therefore unable to account for longitudinal 
changes in these factors on breast cancer risk and survival. 
However, tracking studies have shown that women tend to 
follow a trajectory of BMI, physical activity, blood pres-
sure, and alcohol intake [78–80], suggesting an accumu-
lated lifetime exposure. The sample size narrowed our pos-
sibility of performing further stratified analysis by breast 
cancer subtypes.
In conclusion, our study supports a dose–response 
association between lifestyle behavior and sporadic breast 
cancer. An unfavorable lifestyle may alter biological path-
ways, accelerating tumor growth, and thereby increase 
breast cancer risk, lower the age at onset of sporadic breast 
cancer, and shorten the life expectancy among breast can-
cer patients. Consequently, our results not only support 
a key role of a healthy lifestyle to improve breast cancer 
prevention, but also suggest that tailored personal life-
style advice should be included in daily clinical practice 
of potential importance for treatment outcomes and life 
expectancy for women diagnosed with breast cancer.
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